Bremsstrahlung Enhanced Vascular Brachytherapy Source

轫致辐射增强型血管近距离放射治疗源

• 批准号: 6404455
• 负责人: STEPHEN N BUNKER
• 金额: $ 10万
• 依托单位: IMPLANT SCIENCES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-17 至 2002-12-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6404455
• 关键词: beta radiation; energy source; intraluminal angioplasty; neoplasm /cancer radionuclide therapy; radiation dosage; radionuclide implant; rare earth element; restenosis; technology /technique development

DESCRIPTION (provided by applicant): Restenosis, a major limitation of percutaneous transluminal coronary angioplasty procedures, can be effectively treated by intravascular radiation therapy. Radiation sources currently used for this purpose, however, produce emissions either too penetrating (iridium- 192) or not penetrating enough (strontium-90/yttrium-90 and phosphorus-32) to qualify as ideal. In the former, radiation safety of patient and personnel is an issue, in the latter absorption by arterial plaque or stent wires impacts efficacy. The solution is a radiator with intermediate properties. One such is the high-activity bremsstrahlung-enhanced thulium-170 source Implant Sciences proposes to develop. By making direct use of thulium's native x- and gamma-rays and converting the isotope's beta emissions to supplemental bremsstrahlung, a safe source minimally affected by plaque is obtained. In addition to overcoming the technical negatives of present practices, thulium-based sources, because the source material is inexpensive and readily made, promise the economic advantage of reduced cost. PROPOSED COMMERCIAL APPLICATION: Not available

描述（由申请人提供）：再狭窄，一个主要限制 经皮冠状动脉腔内成形术，可以有效地通过血管内放射治疗进行治疗。目前使用的辐射源 然而，为此目的，产生的发射要么太具有穿透力（铱- 192) 或渗透不够（锶 90/钇 90 和磷 32） 符合理想条件。前者，患者和人员的辐射安全是 一个问题是，后者被动脉斑块或支架线吸收影响 功效。解决方案是使用具有中间性能的散热器。其中之一是 高活性轫致辐射增强铥 170 源 Implant Sciences 建议开发。通过直接利用铥的天然 X 射线和伽马射线 并将同位素的β发射转化为补充轫致辐射， 获得了受牙菌斑影响最小的安全来源。除了克服 现有实践中基于铥的来源的技术缺点，因为 原材料便宜且容易制造，保证经济 降低成本的优点。 拟议的商业应用： 无法使用